{"id":20473,"date":"2014-04-28T12:05:54","date_gmt":"2014-04-28T16:05:54","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=20473"},"modified":"2014-04-28T12:05:54","modified_gmt":"2014-04-28T16:05:54","slug":"athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473","title":{"rendered":"Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For Ulcerative Colitis"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 04\/28\/2014 (wallstreetpr) &#8211;\u00a0<b>Athersys, Inc. (NASDAQ:ATHX)<\/b> reported stem cell study for bowel therapy to fail to show results in mid stage trail.<\/p>\n<p style=\"text-align: justify;\">Athersys announced the results of one of its mid stage studies called MultiStem\u00ae cell treatment for ulcerative colitis. The trail was being conducted by <b>Pfizer Inc. (NYSE:PFE)<\/b> on UC patients and the results demonstrated safe and tolerable affects for MultiStem after a treatment of 8 weeks. The results, however, did not show any remarkable benefits to chronic sufferers having moderate to extreme level UC. The patients under consideration were administered a single dose and have failed to respond positively for any other therapies earlier.<\/p>\n<p style=\"text-align: justify;\">The trail was being conducted by Athersys, Inc. (NASDAQ:ATHX) and Pfizer jointly at various sites including those in the U.S., Europe and Canada. The study included two parts involving a limited dose choosing phase and another efficacy phase. While the first part involved 18 patients, the second involved as many as 88 patients. Of these, 48 belonged to MultiStem treatment and 40 were subjected to the placebo therapy.<\/p>\n<p style=\"text-align: justify;\"><b>Insignificant Results<\/b><\/p>\n<p style=\"text-align: justify;\">The results demonstrate data collected over 8 weeks for patients undergoing cell therapy or being administered placebo. Some initial efficiency endpoints for the trail are also included in the results announced. Additional results for a stretched period of 16 weeks in which a second dose was administered to some of the patients will be announced later by the drug maker.<\/p>\n<p style=\"text-align: justify;\">The highlights of the results announced include safety and tolerability profile of the MultiStem therapy for 8 weeks after treatment. The results marked that the therapy does not show any significant improvement in the condition of chronic sufferers of UC as compared to placebo\u2019s initial efficiency endpoints. It was noticed that after 4 weeks of treatment, some patients showed improved results than placebo, but the benefits were seen declining in some patients as they were significant at all measured time points.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 04\/28\/2014 (wallstreetpr) &#8211;\u00a0Athersys, Inc. (NASDAQ:ATHX) reported stem cell study for bowel therapy to fail to show results in mid stage trail. Athersys announced [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":5121,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[6149,6150,993,2745],"stock_ticker":[],"class_list":["post-20473","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-athersys-inc-nasdaqathx","tag-nasdaqathx","tag-nysepfe","tag-pfizer-inc-nysepfe","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For Ulcerative Colitis - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For Ulcerative Colitis - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 04\/28\/2014 (wallstreetpr) &#8211;\u00a0Athersys, Inc. (NASDAQ:ATHX) reported stem cell study for bowel therapy to fail to show results in mid stage trail. Athersys announced [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-04-28T16:05:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Van Bettauer\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Van Bettauer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473\"},\"author\":{\"name\":\"Van Bettauer\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\"},\"headline\":\"Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For Ulcerative Colitis\",\"datePublished\":\"2014-04-28T16:05:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473\"},\"wordCount\":327,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg\",\"keywords\":[\"Athersys Inc. (NASDAQ:ATHX)\",\"NASDAQ:ATHX\",\"NYSE:PFE\",\"Pfizer Inc (NYSE:PFE)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473\",\"name\":\"Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For Ulcerative Colitis - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg\",\"datePublished\":\"2014-04-28T16:05:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg\",\"width\":400,\"height\":300},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For Ulcerative Colitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\",\"name\":\"Van Bettauer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"caption\":\"Van Bettauer\"},\"description\":\"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For Ulcerative Colitis - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473","og_locale":"en_US","og_type":"article","og_title":"Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For Ulcerative Colitis - Wall Street PR","og_description":"Boston, MA 04\/28\/2014 (wallstreetpr) &#8211;\u00a0Athersys, Inc. (NASDAQ:ATHX) reported stem cell study for bowel therapy to fail to show results in mid stage trail. Athersys announced [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-04-28T16:05:54+00:00","og_image":[{"width":400,"height":300,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg","type":"image\/jpeg"}],"author":"Van Bettauer","twitter_misc":{"Written by":"Van Bettauer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473"},"author":{"name":"Van Bettauer","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d"},"headline":"Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For Ulcerative Colitis","datePublished":"2014-04-28T16:05:54+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473"},"wordCount":327,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg","keywords":["Athersys Inc. (NASDAQ:ATHX)","NASDAQ:ATHX","NYSE:PFE","Pfizer Inc (NYSE:PFE)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473","url":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473","name":"Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For Ulcerative Colitis - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg","datePublished":"2014-04-28T16:05:54+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/12\/Pfizer1.jpg","width":400,"height":300},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/athersys-inc-nasdaqathx-reports-disappointment-in-stem-cell-study-for-ulcerative-colitis-20473#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For Ulcerative Colitis"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d","name":"Van Bettauer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","caption":"Van Bettauer"},"description":"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/20473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=20473"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/20473\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/5121"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=20473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=20473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=20473"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=20473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}